<DOC>
	<DOC>NCT00435916</DOC>
	<brief_summary>This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.</brief_summary>
	<brief_title>Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<criteria>Diagnosis of DLBCL. Received at least one combination chemotherapy regimen with rituximab, such as RCHOP, RESHAP or equivalent. Progression or relapse since most recent therapy. At least one measurable lesion that is both greater than or equal to 2 cm by conventional CT or greater than or equal to 1.5 cm by spiral CT. Previous diagnosis or treatment for indolent lymphoma, leptomeningeal lymphoma, or central nervous system lymphoma. Primary refractory disease. Received an allogenic stem cell transplant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antigens, CD40</keyword>
	<keyword>Antibody, Monoclonal</keyword>
	<keyword>Lymphoma, Large B-Cell, Diffuse</keyword>
	<keyword>Lymphoma, Non-Hodgkin</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Lymphoma</keyword>
</DOC>